Modulating CD39 expression to enhance CAR-T cell therapy against hepatocellular carcinoma

In the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma (HCC), a recent study has identified a pivotal role for CD39 expression in modulating the function of CAR-T cells.

Everything (Maybe) You Wanted to Know About Sarilumab for PMR

Clinicians and others curious about the data underlying February’s FDA approval of sarilumab (Kevzara) for polymyalgia rheumatica (PMR) can now be sated, at least partially,

October 5, 2023

Summit’s Phase 3 data back up biotech’s boasts of beating Keytruda in lung cancer

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 9, 2024

Revitalist Releases Benefits Program Giving Access To All for Ketamine Therapies Changing the Narrative of Mental Health to Risk Mitigation | Psychedelic Invest

Vancouver, British Columbia–(Newsfile Corp. – November 25, 2024) – Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) (the “Company“) announces release of

November 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.